Published in Haematologica on April 01, 2005
Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev (2006) 4.46
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Hemolysis-associated priapism in sickle cell disease. Blood (2005) 1.86
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol (2006) 1.51
Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med (2012) 1.35
Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol (2007) 1.21
β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14
The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management. Eur J Haematol (2007) 1.10
Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest (2010) 1.03
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA (2008) 1.02
Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica (2013) 0.99
Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag (2006) 0.99
Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. Clin Chest Med (2013) 0.95
Pharmacotherapy in sickle cell disease--state of the art and future prospects. Br J Haematol (2009) 0.92
Thalassaemia intermedia: an update. Mediterr J Hematol Infect Dis (2009) 0.88
Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. Lung (2008) 0.84
Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I. Hematology Am Soc Hematol Educ Program (2008) 0.84
Early echocardiographic findings in β-thalassemia intermedia patients using standard and tissue Doppler methods. Pediatr Cardiol (2010) 0.82
Post splenectomy related pulmonary hypertension. World J Respirol (2015) 0.81
Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. Haematologica (2014) 0.80
Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood (2016) 0.80
Non-congenital heart disease associated pediatric pulmonary arterial hypertension. Prog Pediatr Cardiol (2009) 0.78
Pulmonary hypertension in patients with hemoglobinopathies: could a mechanism for dysfunction provide an avenue for novel therapeutics? Haematologica (2005) 0.77
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 0.77
Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature. Pulm Circ (2014) 0.76
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract (2014) 0.76
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia. Ann Thorac Med (2014) 0.75
Echocardiographic evaluation of thalassemia intermedia patients in Duhok, Iraq. BMC Cardiovasc Disord (2014) 0.75
Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management. Mediterr J Hematol Infect Dis (2009) 0.75
Pulmonary hypertension associated with thalassemia syndromes. Ann N Y Acad Sci (2016) 0.75
Review: Hemodynamic Characteristics and Outcomes of Sickle Cell Disease Associated Pulmonary Hypertension. Ethn Dis (2016) 0.75
Response to "efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18. Haematologica (2014) 0.75
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 5.27
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA (2007) 3.32
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica (2005) 2.53
Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet (2011) 2.51
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27
Beta-thalassemia. Genet Med (2010) 2.24
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood (2009) 2.20
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Purging iron from the heart. Br J Haematol (2004) 2.07
Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet (2009) 1.87
Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson (2008) 1.76
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol (2007) 1.74
KLF1 gene mutations cause borderline HbA(2). Blood (2011) 1.71
In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol Dis (2002) 1.70
Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation (2006) 1.69
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol (2013) 1.65
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis (2002) 1.63
Mutational spectrum in congenital dyserythropoietic anemia type II: identification of 19 novel variants in SEC23B gene. Am J Hematol (2010) 1.60
Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin (2003) 1.56
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am (2002) 1.50
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood (2003) 1.46
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol (2011) 1.45
Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica (2009) 1.42
Optimal management of β thalassaemia intermedia. Br J Haematol (2011) 1.41
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol (2014) 1.40
Thrombosis and sickle cell disease. Semin Thromb Hemost (2011) 1.32
Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica (2004) 1.30
How I treat transfusional iron overload. Blood (2012) 1.29
Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Intern Emerg Med (2008) 1.27
Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica (2008) 1.24
Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. Haematologica (2011) 1.23
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica (2011) 1.23
Pathophysiology of beta thalassaemia. Pediatr Endocrinol Rev (2011) 1.22
Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol (2004) 1.22
Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2012) 1.21
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol (2002) 1.21
An update on iron chelation therapy. Blood Transfus (2012) 1.19
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol (2009) 1.16
A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica (2008) 1.16
International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging (2010) 1.14
Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Prefer Adherence (2013) 1.13
Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica (2008) 1.13
A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol (2011) 1.12
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation (2013) 1.11
Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis (2009) 1.10
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica (2011) 1.10
Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med (2010) 1.10
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood (2013) 1.08
Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One (2011) 1.08
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment. Am J Hematol (2015) 1.07
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica (2012) 1.07
Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol (2005) 1.07
Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation (2013) 1.06
Effect of consanguinity on screening for thalassemia. N Engl J Med (2002) 1.05
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica (2010) 1.04
Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Hum Gene Ther (2007) 1.03
Gene test review. Alpha-thalassemia. Genet Med (2011) 1.02
Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. Eur J Intern Med (2011) 1.01
The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine. Intern Emerg Med (2009) 1.00
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica (2014) 1.00
Association of α globin gene quadruplication and heterozygous β thalassemia in patients with thalassemia intermedia. Haematologica (2009) 1.00